Oncogene expression in tumour cells of pediatric Hodgkin's disease in Argentina - Correlation with Epstein Barr virus presence

Pathology Research and Practice

Volumn 194, Issue 1, 1998, Pages 25-31

  Preciado, Maria Victoria ^a   Cristobal, Eva ^b   Menarguez, Javier ^b   Montero, Juan Carlos Martinez ^c   Diez, Blanca ^a   De Matteo, Elena ^a   Grinstein, Saúl ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Ophthalmic Institute   (Spain)

Author keywords

bcl 2; Epstein Barr virus; Hodgkin's disease; mdm2; p21(waf 1); p53; Pediatric

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; VIRUS PROTEIN;

ADOLESCENT; ARGENTINA; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; REED STERNBERG CELL;

EID: 0031905437     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(98)80008-3     Document Type: Article

References (49)

1. Armstrong A, Gallagher A, Krajewski A, Jones D, Wilkins B, Onions D, Jarret R (1992) The expression of EBV LMP-1 is independent of CD23 and bcl-2 in Reed Sternberg cells in Hodgkin's Disease. Histopathology 21: 72
2. Baichwal V, Sugden B (1988) Transformation of BALB/3T3 cells by the BNLF-1 gene of EBV. Oncogene 2:461-467
3. Barak Y, Juven T, Haffner R, Oren M (1993) MDM2 expression is induced by wild type p53 activity. EMBO J 12: 461-468.
4. Carbone P, Kaplan H, Musshoff K (1971) Report of the Committee on Hodgkin's Disease staging classification. Cancer Res 31: 1860-1861
5. Claviez A, Tiemann M, Peters J, Kreipe H, Schneppenheim R, Parwaresch R (1994) The impact of EBV, proliferation rate and bcl-2 expression in Hodgkin's Disease in childhood. Ann Hematol 68: 61-66
6. Doussis I, Pezzella F, Lane D, Gatter K, Mason D (1993) An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's Disease. Am J Clin Pathol 99: 663-667
7. El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J, Lin D, Mercer E, Kinzler K, Vogelstein B (1993) Waf-1, a potential mediator of p53 tumour suppression. Cell 75: 817-825
8. Elenitoba-Johnson K, Medeiros J, Khorsand J, King T (1996) p53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's Disease. Am J Clin Pathol 106: 728-738
9. Fakharzadeh S, Trusko S, George D (1991) Tumourigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J 10: 1565-1569
10. Finlay C, Hind P, Levine A (1989) The p53 protooncogene can act as a suppressor of transformation. Cell 57: 261-265
11. Glaser S, Lin R, Stewart S, Ambinder R, Jarret R, Brouset P, Pallesen G, Gulley M, Khan G, O'Grady J, Hummel M, Preciado MV, Knecht H, Chan J, Claviez A (1997) EBV-associated Hodgkin's Disease: epidemiologic characteristics in international data. Int J Cancer 70: 375-382
12. Gown A, de Weber N, Battifora H (1993) Microwave-based antigen unmasking. A revolutionary new technique for routine immunohistochemestry. Appl Immunohistochem 1: 256-266
13. Gupta R, Norton A, Lister A, Bodmer J (1993) p53 protein expression in Reed-Sternberg cells of Hodgkin's Disease. Leukemia 7 (suppl 2): S31-S33
14. Gupta R, Patel K, Bodmer J (1993) Mutations of p53 in primary biopsy material and cell lines from Hodgkin Disease. Proc Natl Acad Sci USA 90: 2817-2821
15. Gutierrez M, Bhatia K, Diez B, Sackmann Muriel F, Epelman S, De Andreas M, Huppi K, Magrath Y (1994) Prognostic significance of p53 mutations in small noncleaved cell lymphomas. Int J Oncol 4: 567
16. Harris N, Jaffe E, Stein H, Banks P, Chan J, Clearly M, Delsol G, De Wolf-Peeters C, Falini B, Gatter K, Grogan T, Isaacson P, Knowels D, Mason D, Muller-Hermelink H, Piliri S, Piris M, Ralfkiaer E, Warnke R (1994) A revised European Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392
17. Hockenbery D, Nunez G, Milliman C, Schreiber R, Korsmeyer S (1990) Bcl-2 is a inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334
18. Hollstein M, Sidransky D, Vogelstein B, Harris C (1991) p53 mutation in human cancers. Science 253: 49-53
19. Inamura J, Miyoshi I, Koeffler P (1994) P53 in hematological malignancies. Blood 84: 2412-2421
20. Inghirami G, Frizzera G (1994) Role of the bcl-2 oncogene in Hodgkin's Disease. Am J Clin Pathol 101: 681-683
21. Jiwa N, Kanavaros P, Van der Valk P, Walboomers J, Horstman A, Vos W, Mullink H, Meiger C (1993) Expression of c-myc and bcl-2 oncogene products in Reed Sternberg cells independent of presence of EBV. J Clin Pathol 46: 211-217
22. Kern S, Kinzler K, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (1991) Identification of p53 as a sequence-specific DNA binding protein. Science 252: 1708-1711
23. Khan G, Gupta R, Coates P, Slavin G (1993) EBV infection and bcl-2 protooncogene expression. Separate events in the pathogenesis of Hodgkin's disease?. Am J Pathol 143: 1270-1274
24. Korsmeyer S (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886
25. Lane D (1992) p53, guardian of the genome. Nature 358: 15-15
26. Liebowitz D, Kieff E (1989) EBV LMP-1: induction of B cell activation antigens and membrane patch formation does not require vimentin. J Virol 63: 4051-4054
27. Lones M, Pinkus G, Shintaku P, Said J (1993) Bcl-2 oncogene protein is preferentially expressed in Reed Sternberg cells in Hodgkin's Disease of the nodular sclerosis subtype. Am J Clin Pathol 102: 464-467
28. Lukes R, Craver L, Hall T, Rappaport H, Ruben P (1966) Report of Nomenclature Committee. Cancer Res 26: 1311
29. Momand J, Zambetti G, Olson D, George D, Levine A (1992) The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated trans-activation. Cell 63: 1237-1245
30. Niedobitek G, Rowlands D, Young L, Herbst H, Williams A, Hall P, Padfield J, Rooney N, Jones L (1993) Overexpression of p53 in Hodgkin's Disease: lack of correlation with EBV infection. J Pathol 169: 207-212
31. Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K, Bigner S, Davidson N, Baylin S, Devilee P, Glover T, Collins F, Weston A, Modali R, Harris C, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
32. Pallesen G, Hamilton-Dutoit S, Rowe M, Young L (1991) Expression of EBV latent gene products in tumour cells of Hodgkin's Disease. Lancet 337: 320-322
33. Pezzella F, Tse A, Cordell J, Pulford K, Gatter K, Mason D (1990) Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol 137: 225-232
34. Piris M, Pexella F, Martinez-Montero JC, Orradre J, Villuendas R, Sanchez-Beato M, Cuena R, Cruz M, Martinez B, Garrido M, Gatter K, Aiello A, Delia D, Giardini R, Rilke F (1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69: 337-341
35. Preciado MV, De Matteo E, Diez B, Grinstein S (1995) EBV LMP in tumour cells of Hodgkin's Disease in pediatric patients. Medical and Pediatric Oncology 24: 1-5
36. Preciado MV, De Matteo E, Diez B, Menarguez J, Grinstein S (1995) Presence of EBV and strain type assignment in Argentine childhood Hodking's Disease. Blood 86: 3922-3929
37. Preciado MV, Diez B, Grinstein S (1997) EBV in Argentine childhood Hodgkin's Disease. Leukemia and Lymphoma 24: 283-290
38. Prokocimer M, Rotter V (1994) Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematological cell lineages. Blood 84: 2391
39. Racevskis J, Wiernik P, Kirshner E, Raghavan V, Paietta E (1995) Absence of hereditary p53 mutations in eight familial Hodgkin's disease pedigrees. Leukemia 9: 1966-1969
40. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E (1990) EBV types 1 and 2 differ in their EBNA-3A, EBNA-3B and EBNA-3C genes. J Virol 64: 4084-4092
41. Sarnow P, Ho Y, Williams J, Levine A (1982) Adenovirus Elb-58kD tumour antigen and SV40 large tumour antigen are physically associated with the same 54kD cellular protein in transformed cells. Cell 28: 387-394
42. Tao Q, Srivastava G, Loke S, Ho F (1994) Lack of correlation between expression of EBV LMP-1 and bcl-2 oncoprotein in vivo. J Clin Pathol 47: 589-591
43. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms establish rodent cells. Cell 43: 831-840
44. Weiss L, Mohaved L, Warnke R, Sklar J (1989) Detection of EBV genomes in Reed Sternberg cells of Hodgkin's Disease. N Engl J Med 320: 502-506
45. Werness B, Levine A, Howley P (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79
46. Wright C, Reid A, Tsai M, Ventre K, Murari P, Frizzera G, O'Learly T (1991) Detection of EBV sequences in Hodgkin's Disease by the polymerase chain reaction. Am J Pathol 139: 393-398
47. Wu T, Mann R, Charache P, Hayward D, Staal S, Lambe B, Ambinder R (1990) Detection of EBV gene expression in Reed Sternberg of Hodgkin's Disease. Int J Cancer 46: 801-804
48. Wu X, Bayle H, Olson D, Levine A (1993) The p53-MDM2 autoregulatory feedback loop. Genes & Dev 7: 1126-1132
49. Xerri L, Pare P, Bouabdallah R, Camerlo J, Hassoun J (1994) PCR mismatch analysis of p53 gene mutations in Hodgkin's Disease. J Pathol 175: 189-194